Global Medical Food and FSMP Market Entry: Navigating Regulatory Pathways and Commercial Strategy

Medical foods and FSMPs worldwide: a practical creation and registration playbook

This playbook covers a finished, orally or enterally administered nutritional product intended for dietary management under healthcare-professional supervision. It does not cover parenteral nutrition, conventional supplements, infant formula, or a product marketed to treat, prevent, or cure disease. Those boundaries are decisive: the United States treats a medical food as a narrowly defined food for enteral use under physician supervision and for a disease or condition with distinctive nutritional requirements that cannot be managed by normal-diet modification alone. It is not simply a product a clinician recommends.[1]

The central commercial mistake is to start with a supplement proposition and then add medical language. Build the product around a demonstrable disease-linked nutritional need, an intended patient population, an appropriate nutritional format (complete, nutritionally incomplete/module, or disease-specific complete), and professional supervision. In the EU, FSMPs are foods for dietary management under medical supervision; the framework explicitly addresses people with specified diseases, disorders, or medical conditions.[2] In Australia and New Zealand, the category similarly covers patients whose nutritional requirements cannot be met by normal foods and includes both sole-source and supplementary products.[3]

The regulatory map: five operating models

United States — medical food / food-facility route

There is no product-by-product FDA premarket approval or FDA list of medical foods. The facility, including a foreign facility, must be registered; the manufacturer remains responsible for food safety, lawful ingredients, compliant labeling, and substantiation that the product fits the narrow medical-food definition.[1] This is fast only when the intended use and ingredients are clearly defensible; it is not a shortcut for a disease-treatment claim.

EU/EEA and UK — FSMP framework plus national notification

The EU framework is harmonised for the category and Delegated Regulation (EU) 2016/128 sets specific compositional and information requirements for FSMP.[4] Market placement commonly requires a national notification to the competent authority in the first Member State of sale, and national practice matters especially for borderline classification, language, and dossier expectations. The UK has retained a Food for Specific Groups regime; use a UK-specific notification/label review rather than assuming an EU notification travels automatically.[5]

China — registration-led FSMP regime

China is the highest-regulatory-investment market in this map. The rule applies to domestic production, import, and sale; SAMR administers registration.[6] The dossier includes applicant qualification, R&D report, formula and design rationale, process, product standard, label/instructions, testing, and evidence of safety, nutritional adequacy, and medical-purpose clinical effect; disease-specific complete-nutrition formulas generally also need a clinical-trial report.[6] The stated technical-review clock is 60 working days, extendable by 30, but supplement requests, testing, and site inspection sit outside that clock.[6]

Australia/New Zealand — FSMP standard and controlled sale

Standard 2.9.5 regulates composition, labelling, and sale. The label must identify medical supervision and the medical purpose; sole-source products have mandatory nutrient requirements, with stated condition-specific variation where applicable.[3] Sale is limited to defined professional/institutional/distributor channels, not open retail.[3]

Food-for-special-dietary-use / local food-control regimes

Canada, Brazil, India, much of ASEAN, Latin America, MEA, and parts of East Asia do not share one portable FSMP registration route. The practical task is a written local classification decision before committing to claims, packaging, or clinical work. Canada, for example, regulates formulated liquid diets under its food-for-special-dietary-use rules; a product represented as a nutritionally complete oral or tube-fed diet has explicit composition and label requirements.[7, 8] Brazil separately subjects standard, modified, paediatric enteral formulas and enteral modules to Anvisa marketing authorization.[9]

Create the product in the right order

1. Write a global Target Product Profile before formulation freeze

   Specify: disease/condition; the distinctive nutritional requirement; age; route (oral, tube, or both); whether complete or supplemental; daily intake; duration; contraindications; and supervision model. The intended-use statement must say “dietary management,” not “treats” or “prevents.” In the US, an ordinary modified diet must be insufficient; FDA expressly views diabetes and pregnancy propositions as generally unsuitable medical-food indications where needs can be met through normal-diet modification.[1]

2. Build a dossier that can be modularised

   Use one scientific core dossier and local modules:

   • Identity and classification: category rationale, comparator products, intended use, professional-supervision plan.

   • Nutritional rationale: disease mechanism, nutrient limitation/excess/altered requirement, formulation logic, daily intake and safety margins.

   • Clinical evidence: not necessarily an efficacy trial in every market, but credible evidence that the formulation addresses the defined nutritional need. China is the material exception for certain disease-specific complete formulas, where a clinical-trial report is generally required.[6]

   • Quality and manufacturing: supplier qualifications, specifications, manufacturing-flow diagram, batch testing, shelf life, stability, microbiological control, allergens, and change control. China expects R&D, manufacturing, and testing capability and a GMP-appropriate quality system.[6]

   • Label and artwork: master artwork plus country overlays, translations, nutrient declaration, allergen statements, age/patient limitations, preparation/storage, supervision language, and local importer details.

3. Treat claims as a classification control

   Medical-food/FSMP language permits a nutrition-management proposition, not a therapeutic promise. China requires a physician-or-clinical-nutritionist supervision statement and prohibits disease prevention/treatment claims and nutrient function claims on FSMP labels and instructions.[6] Singapore is an example of a market in which food nature versus medicinal purpose, dosage form, and presentation can move a product across agency boundaries; the authorities advise obtaining a classification confirmation when uncertain.[10]

4. Design quality for local label tolerances

   Do not use a single global nutrition panel without local reconciliation. Canada, for example, applies Division 24 nutrient-label rules to formulated liquid diets and requires declared nutrient values at both sale and ready-to-serve basis; it also uses defined analytical compliance tolerances.[8] Establish an internal release specification tighter than the most restrictive intended-market declaration tolerance.

Priority-market launch sequence

Wave 1

US, EU lead Member State, UK, Australia, China, Japan, South Korea, Canada, Brazil, India, Singapore, and Saudi Arabia/UAE. These markets either create a distinct registration/classification burden, set a large regional precedent, or are strategically important import hubs. Start China in parallel only after formula and clinical strategy are mature; do not make it the first formulation-learning market.[1, 3, 4, 6, 9]

Wave 2

New Zealand (with Australia), Switzerland, Taiwan, Malaysia, Thailand, Indonesia, Vietnam, Philippines, Mexico, Chile, Colombia, South Africa, Turkey, Israel, and Kuwait. Reuse the core dossier, but seek country-level classification and importer/label confirmation.[3, 10, 11]

Wave 3

remaining EU/EEA countries, CEE, and local-distributor markets. Use the established EU FSMP dossier and labels as the scientific core, but execute national notifications and language artwork country by country.[2, 4]

Market-specific execution notes

United States

• Confirm each formula meets the enteral-use, distinctive-nutritional-requirement, medical-supervision, and ongoing-medical-care tests before any launch claim.[1]

• Register each applicable food facility; this is facility registration, not product clearance.[1]

• Use conventional food label basics—identity, net quantity, responsible business, ingredient list—and avoid Rx only or NDC language.[1]

• Vet each ingredient as lawful and safe for the intended use; the FDA guidance identifies food additives, color additives, GRAS substances, or prior-sanctioned substances as possible lawful bases.[1]

European Union, United Kingdom, Switzerland, Norway

• Qualify the product under the FSMP definition before notification; keep a product-specific classification memo and clinical/nutritional dossier. EFSA’s FSMP guidance describes a structured dossier format and the data used to assess category fit.[12]

• Map each launch country’s notification recipient, notification timing, fee, electronic format, language, label submission, and local food-business-operator requirements.

• Keep the marketing claim tethered to dietary management under medical supervision. The EU framework protects vulnerable groups through content and marketing rules; it is not a drug approval route.[2]

• Treat Switzerland and Norway as separate national implementations despite close alignment with European norms; obtain country-specific classification and language sign-off.

China

• Select the statutory category early: infant FSMP or, for age 1+, complete nutrition, disease-specific complete nutrition, or nutritionally incomplete formula.[6]

• Use the Chinese manufacturing/import applicant structure and prepare for document review, manufacturing-site inspection, sample testing, and—where relevant—clinical-trial inspection.[6]

• Build Chinese label and instructions as controlled dossier items. The label must show the product name, registration number, intended population, and medical/clinical nutrition supervision statement; it must not make prevention or treatment claims.[6]

• Plan lifecycle work: the registration certificate is valid for five years; changes affecting formula or process can trigger substantive review.[6]

Australia and New Zealand

• Demonstrate that normal food cannot meet the target group’s nutritional needs and select sole-source versus supplementary status.[3]

• Meet Standard 2.9.5 composition and label requirements; use the prescribed professional/institutional channel strategy.[3]

• Exclude parenteral nutrition, infant formula, and obesity/overweight dietary-management products from the FSMP route.[3]

Canada and Brazil

• Canada: determine whether the product is a formulated liquid diet or another Division 24 category. Formulated liquid diets are complete diets for oral or tube feeding; label requirements include use route, nutrient declaration, preparation/use, storage, and expiry.[8]

• Brazil: use the Anvisa authorization route for the regulated enteral formula category; a Brazil-based manufacturer, legal representative, or importer may be eligible to request authorization, and the applicant must be the product owner.[9]

India, ASEAN, Japan, South Korea, GCC, and the rest of Latin America

• These markets require local product classification before a purported “FSMP registration” plan is finalised. India’s FSSAI draft framework expressly contains a food-for-special-medical-purpose category, but current operative requirements, notifications, and product-specific interpretations must be verified with Indian regulatory counsel before filing.[13] In Singapore, importers must ensure food compliance with the Food Regulations, while product classification may require SFA/HSA confirmation.[10]

• For Japan, South Korea, Taiwan, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Saudi Arabia, UAE, Kuwait, Turkey, Israel, Mexico, Chile, Colombia, Argentina, Peru, and South Africa, treat the following as a pre-filing gate (a conservative approach where the initial official-source review did not identify a portable FSMP route):[10]

  1. authoritative classification opinion;
  2. local company/importer and licensing;
  3. status of ingredients and additives;
  4. route and age limits;
  5. local-language label and permitted claims;
  6. premarket notification/registration or import clearance; and
  7. customs/health certificate, halal or other conformity requirements where relevant.
  Do not assume a supplement authorization, US facility registration, EU FSMP notification, or China FSMP registration substitutes for this local route.

Country launch matrix

This matrix is integrated from the companion country launch table. “Classification first” means the local category and filing route should be confirmed in writing before a registration timeline is committed.

Notification and registration plans for priority regions

1. United States — classification and facility-registration plan

Regulatory outcome: a defensible medical-food launch; not a product approval. FDA does not require medical foods to undergo premarket review or approval, but applies food-facility registration and food-law requirements.[1]

Prepare a two-to-four page medical-food classification memorandum against each statutory and regulatory criterion: specially formulated/processed, oral or enteral use, disease-specific distinctive nutritional requirement, normal-diet insufficiency, medical supervision, and ongoing medical care.[1]

Produce the ingredient legal-basis file (food additive, color additive, GRAS, or prior sanction as appropriate), specifications, allergen assessment, and safety substantiation.[1]

Register each required domestic or foreign food facility; appoint the required foreign-facility representation where applicable. Do not seek or represent “FDA approval” of the product.[1]

Approve US artwork: identity, net quantity, responsible party, ingredients, allergens, English mandatory information, and a truthful supervision statement. Do not use Rx only or an NDC.[1]

Establish post-market controls: complaint and recall SOPs, batch/nutrition verification, adverse-event escalation, claims review, and product-change assessment.

Go/no-go gate: a clinician must be able to explain why the product is necessary for dietary management of the named condition and why a normal-diet modification alone is not sufficient. A diabetes or pregnancy general-use proposition is a high-risk example under FDA’s published interpretation.[1]

2. European Union and EEA — FSMP notification plan

Regulatory outcome: EU FSMP-qualified product placed on the market through country-specific notification and local execution. Regulation (EU) 609/2013 establishes the food-for-specific-groups framework and Delegated Regulation (EU) 2016/128 supplies FSMP-specific composition/information requirements.[2, 4]

Choose the lead Member State and appoint the food business operator/importer responsible for first placement.

Create the EU core dossier: classification rationale, target patients, disease-linked nutritional requirement, normal-food insufficiency, formula/composition, evidence, safety, directions, supervision model, and representative label. EFSA’s published FSMP guidance provides a dossier organisation and identifies the key information used to assess FSMP scope.[12]

Conduct a national notification check for every target Member State before launch. Confirm the authority, timing, dossier format, fee, language, local establishment/representative, whether the exact label is required, and any post-notification correspondence procedure.

Localise label and instructions without changing the scientific proposition. Maintain a country-by-country translation log and back-translation approval.

File the first-market notification, retain submission evidence, then execute subsequent national notifications before each additional launch.

Use one EU change-control assessment for formula/process/claim changes and a country overlay to decide whether a re-notification is needed.

Go/no-go gate: the product must be credibly a food for dietary management under medical supervision rather than an ordinary food, supplement, or therapeutic presentation.[2]

3. United Kingdom — separate retained-law plan

Regulatory outcome: UK-compliant FSMP launch, treated independently from the EU. UK food-for-specific-groups legislation is separate from the EU regime.[5]

Build from the EU core dossier but run a UK classification, notification, and label review.

Confirm the correct UK authority and process for the intended territory, the UK responsible food business operator, filing timing, artwork, and retention records.

Keep UK labels and digital claims controlled separately from EU artwork; do not presume EU notification evidence is a UK filing.

Add the UK to global change control, including review of regulatory divergence.

4. China — SAMR FSMP registration plan

Regulatory outcome: registered FSMP, not an import-only notification. China’s rule applies to domestic production, import, and sale, and SAMR administers registration.[6]

Select the legal category and intended population before design freeze: infant FSMP or, for people aged 1+, complete nutrition, disease-specific complete nutrition, or nutritionally incomplete formula.[6]

Hold a pre-submission strategy review around the formula, clinical development, manufacturing site, inspection readiness, analytical methods, Chinese label, and instructions.

Assemble the registration dossier: applicant qualification; R&D report; formula/design rationale; manufacturing process; product standards/technical requirements; artwork; testing; manufacturing/R&D/testing capability; and evidence of safety, nutritional adequacy, and special-medical-purpose clinical effect.[6]

For disease-specific complete nutrition formulas, plan a clinical trial report and clinical-trial inspection readiness; clinical evidence should be initiated early enough to avoid blocking the filing.[6]

Run facility mock inspection and batch-record reconciliation before filing. The authority may inspect manufacturing and clinical sites and test dynamically produced samples.[6]

File and manage questions as one controlled evidence package. The formal technical review is 60 working days, extendable by 30, while supplemental-material time and certain inspections/testing are outside the clock.[6]

Lock the approved Chinese label: product name, registration number, target population, and physician/clinical-nutritionist supervision statement; exclude prevention, treatment, and nutrient function claims.[6]

Maintain a five-year renewal calendar and assess every formula/process change before implementation.[6]

Go/no-go gate: a formula, dossier, and manufacturing/clinical-inspection package that are consistent with each other—not merely a finished commercial label.

5. Australia and New Zealand — FSMP standard and channel plan

Regulatory outcome: Standard 2.9.5-compliant FSMP with an appropriate professional supply channel. The standard regulates FSMP composition, labelling, and sale; it also restricts sale to specified practitioner, institution, pharmacy, or distributor channels.[3]

• Confirm the product is not excluded: infant formula, parenteral nutrition, or a product represented for dietary management of obesity/overweight.[3]
• Determine sole-source versus supplementary use; map each mandatory nutrient and any disease-specific permitted variation.
• Finalise label: medical supervision, medical purpose, sole-source suitability, ingredients, allergens, and date marking.[3]
• Contract only through a permitted practitioner/institution/pharmacy/distributor model and train each counterparty on the permitted product proposition.[3]
• Create an Australia/New Zealand shared dossier, then confirm any jurisdictional commercial/import overlay before release.

6. Canada and Brazil — priority Americas plans

Canada

First classify the product as a formulated liquid diet or a different food-for-special-dietary-use category. A formulated liquid diet is a nutritionally complete diet for oral or tube feeding of a person with disease/disorder/injury-related needs.[7] Build the Division 24 formula and label review around route of use, nutrient declaration, preparation, storage, and expiry; release testing must support the declared values.[8]

Brazil

First confirm that the product is an Anvisa-authorised enteral formula or module; standard, modified, paediatric enteral formulas and enteral modules are listed as marketing-authorization categories.[9] Establish the Brazilian product owner and eligible applicant—manufacturer, Brazil legal representative, or importer—then compile the product authorization package and change-control process.[9]

7. Classification-first notification plan for APAC, GCC, and non-harmonised markets

For Japan, South Korea, Taiwan, India, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Saudi Arabia, UAE, Kuwait, Turkey, Israel, Mexico, Chile, Colombia, Argentina, Peru, South Africa, Ukraine, and Egypt, use this sequence before setting a filing date:

• Submit a concise classification request package to the competent food/health authority or obtain a written opinion from qualified local counsel.
• Include formula, intended patients, daily intake, dosage form, route, proposed labels/claims, supervision language, clinical/nutrition summary, and comparator products.
• Obtain an answer on category, local legal entity/importer, premarket filing, product standards, label language, claim constraints, import certificate, and halal/kosher requirements where relevant.
• Convert the answer into a country-specific filing checklist, launch timing, and change-control rule.

Singapore illustrates why this gate is necessary: food-nature products are administered by SFA, while health products can fall under HSA; the agencies identify classification as dependent on multiple factors and advise confirmation where uncertain.[10]

EU authority portals and notification fees

The Union baseline is a notification to the competent authority in each Member State where the FSMP is marketed, using the product label and any further compliance information requested; a Member State can operate a national efficient-monitoring exemption.[14] Portal and fee data are national, not harmonised. The table therefore distinguishes verified entries from fields that should be confirmed directly with the national authority before the local launch budget is approved. A blank or “confirm” entry is not evidence that no fee or notification applies.

How to complete the “confirm” rows

For each Member State, send the local authority a controlled one-page inquiry with product category, target patient group, label language, local food-business operator, and planned first-marketing date. Ask for:

1. the FSMP notification portal or email/address;
2. whether Article 9 notification is required or exempted;
3. the current initial and change-notification fee, payment method, and VAT treatment;
4. required attachments and translations;
5. confirmation/receipt timing; and
6. the change-notification trigger.

This is necessary because Article 9 allows national monitoring systems to differ.[14]

Regional regulation index: the documents that should sit in the launch dossier

This is a working legal index, not a substitute for consolidated national law or a local legal opinion. It links the core, confirmed instruments used in this playbook and identifies the primary authority to check where an FSMP-specific instrument was not verified in the initial review.[14]

Europe: EU/EEA, United Kingdom, Switzerland, and Turkey

EU / EEA — Regulation (EU) 609/2013, Food for Specific Groups. The framework regulation for FSMPs, infant and young-child food, and total diet replacement. It establishes the vulnerable-consumer framework and underpinning category. Official European Commission overview.[2]

EU / EEA — Commission Delegated Regulation (EU) 2016/128. The core FSMP instrument: categories, composition, mandatory information, nutrition declaration, claims prohibition, infant-specific marketing restrictions, and Article 9 notification. Consolidated official text.[14]

EU / EEA — Regulation (EU) 1169/2011. General food-information law, applied to FSMPs except where 2016/128 supplies specific rules.[14]

EU / EEA — Commission Notice on FSMP classification. Use it as the EU classification reference for borderline products, together with the product-specific clinical/nutritional dossier. Official notice.[15]

United Kingdom — Food for Specific Groups (Information and Compositional Requirements) (England) Regulations 2016, with later amendments. Use the retained UK regime and UK authority process rather than treating an EU notification as transferable. UK legislation information sheet.[5]

Switzerland — Swissmedic/FSVO boundary criteria for orally administered products. Use this before deciding the food versus therapeutic-product route. Official guidance.[11]

Turkey — verify the current Ministry of Agriculture and Forestry food-category and import regime. Do not use EU FSMP compliance as a substitute for Turkish classification, Turkish artwork, or local import clearance.

Asia-Pacific

China — SAMR Measures for the Registration of Foods for Special Medical Purpose (Order No. 85, effective 1 January 2024). The central registration rule for domestic, imported, and marketed FSMPs. Official text.[6]

China — supporting registration guidance and national FSMP food-safety standards. Build product category, formula, clinical, manufacturing, test, and Chinese label work against these supporting materials as well as Order No. 85; they control the practical submission package.[6]

Australia and New Zealand — Australia New Zealand Food Standards Code, Standard 2.9.5: Food for Special Medical Purposes. Controls FSMP composition, labelling, sale and supply channel. FSANZ overview.[3]

India — FSSAI Food Safety and Standards framework for health supplements, nutraceuticals, food for special dietary use and food for special medical purpose. The reviewed FSSAI material was a draft 2022 framework; confirm the current operative notification and category interpretation before building or filing. FSSAI document.[13]

Singapore — Sale of Food Act / Food Regulations and the SFA–HSA classification framework. The useful regulatory instrument is the classification boundary, which directs food-nature products to SFA and health products to HSA. Official classification tree.[10]

Japan, South Korea, Taiwan, Malaysia, Indonesia, Thailand, Vietnam, Philippines, and other APAC markets — local special-purpose food / food-health-product rules. Obtain the current primary instrument and a written category position from the relevant national authority before choosing a route; this playbook does not treat a supplement regime as an FSMP rule.

North America and Latin America

United States — Orphan Drug Act medical-food definition and FDA medical-food guidance. The definition requires enteral use under physician supervision and dietary management of a disease or condition with distinctive nutritional requirements. FDA guidance landing page.[1, 29]

United States — FD&C Act food requirements and FDA food-facility registration rules. Medical foods are not drugs and do not undergo product premarket approval; applicable facilities register and the product must meet food-law obligations.[1]

Canada — Food and Drug Regulations, Division 24 (Foods for Special Dietary Use). Central for formulated liquid diets and associated composition/label rules. Regulation.[7]

Canada — CFIA labelling requirements for foods for special dietary use. Use for formulated-liquid-diet declaration, directions, storage, expiry, and compliance-testing detail. CFIA guidance.[8]

Brazil — RDC 843/2024 and IN 281/2024. These establish food market-authorization pathways and identify standard, modified, paediatric enteral formula and enteral modules as Anvisa authorization categories. Anvisa overview.[9]

Mexico, Colombia, Chile, Argentina, and Peru — national food/health-product and import rules. Seek an authority-specific classification of the finished product before selecting a filing route; no directly verified harmonised Latin American FSMP instrument was identified in the initial review.

Middle East and Africa

Saudi Arabia, UAE, Kuwait, Egypt, South Africa, Israel — national food/health-product classification, import, label, and conformity systems. Obtain a category determination for the exact formulation, claims, presentation, and supply model before setting a filing route.

Halal and kosher documentation. Confirm whether the target route, customer, or tender requires them. They do not replace FSMP classification or food-market authorization.

Common global references

Codex Alimentarius — Standard for Foods for Special Medical Purposes (CODEX STAN 180-1991). Use as an international technical comparator where a local authority asks for an international basis, but never assume it overrides the applicable national FSMP/medical-food law.

Product-specific evidence and quality file. Whatever the jurisdiction, retain the classification rationale, disease-linked nutritional need, formula and nutrition data, safety/quality file, label, and post-market change assessment. EU law requires that an FSMP formulation be based on sound medical and nutritional principles and be safe, beneficial, and effective for the intended nutritional requirements as demonstrated by generally accepted scientific data.[14]

Formulation, evidence, and classification clarifications

Engineering controls for oral and enteral products

The article previously covered formulation logic, stability, and labelling, but the development plan now makes enteral usability a formal design-control stream. For every oral or tube-fed formula, define acceptance criteria for osmolality/osmolarity where relevant, viscosity across shelf life and administration temperature, powder reconstitution, microbial robustness after opening, thermal-process stability, nutrient recovery at end of shelf life, and compatibility with the intended feeding set and tube size. EU FSMP labelling must include osmolality or osmolarity where appropriate, as well as the source/nature of protein or hydrolysates; formulation must be safe, beneficial, and effective for the target nutritional requirement on generally accepted scientific data.[14]

Practical acceptance package: analytical release tests; accelerated and real-time stability; preparation-use simulation; tube-flow/occlusion testing for any enteral claim; sensory work for oral use; and target-population tolerance monitoring. These are product-development controls, not a substitute for the jurisdiction-specific regulatory dossier.[14]

Clinical evidence: use a claim-linked strategy, not a universal trial rule

Human evidence should be proportional to the category, patient vulnerability, formula novelty, and claim/rationale. It should show that the finished product can meet the stated nutritional need safely and as intended. The EU rule requires the formulation to be based on sound medical and nutritional principles and supported by generally accepted scientific data; it does not create a uniform premarket clinical-trial requirement for every FSMP.[14]

China is the major explicit exception in the reviewed materials: for a disease-specific complete-nutrition formula, the registration dossier generally includes a clinical-trial report, and the authority may inspect clinical-trial conduct.[6] Do not assume that a clinical trial must be local merely because the filing is in China; build the protocol, sites, data integrity, and inspection strategy against the current SAMR requirements and pre-submission advice.

Corrections to common but risky shorthand

National standards, permitted raw-material lists, manufacturing licences, and exact clinical-evidence expectations can change and are not globally portable. The playbook therefore uses China’s registration rule and national food-safety standards as a controlled-country dossier workstream, rather than treating a cited GB number, US GRAS status, or EU formula as a universal specification.[6]

Critical controls added after regulatory-gap review

Four operational controls are sufficiently material that they should be formal launch gates rather than appendices to the marketing dossier.

1. Ingredient status comes before FSMP notification

FSMP classification does not cure an ingredient-authorisation problem. In the EU, a food not consumed to a significant degree before 15 May 1997 can be a novel food; pre-market authorisation is required before it is placed on the Union market.[30] Where novelty is uncertain, the food business operator should consult the competent authority of the first intended EU market.[30] In parallel, check the EU Union list for the permitted forms, specifications, conditions of use, and any additional label or post-market requirements.[31]

For FSMPs, also run every vitamin, mineral, amino acid, and other nutritional substance against the Regulation (EU) 609/2013 Union list and any required authorisation route. The Commission identifies that Annex as the single Union list for substances added to foods for specific groups and directs requests for inclusion through the E-submission Food Chain Platform.[32]

Launch gate: no formula freeze until each ingredient has a documented legal basis in every target market, including its chemical form, specification, dose, intended population, and labelling conditions.[30, 32]

2. Importer compliance is separate from product notification

For US imports, identify the FSVP importer at entry and ensure that importer has a compliant foreign-supplier-verification programme; the FSVP rule is in 21 CFR part 1, subpart L. The FSVP importer may not be the same entity as the customs importer of record.[33] This sits alongside—not instead of—FDA food-facility registration and the medical-food classification case.[1]

For every non-domestic launch, the country checklist should identify: importer of record, food-business operator or local representative, manufacturer/site identifiers, customs tariff and document requirements, health certificate needs, and the party that owns the local notification and artwork. This keeps import accountability distinct from product notification.[1, 33]

3. Traceability, withdrawal, and recall must be designed into the supply chain

In the EU, food businesses must keep supplier and customer information in an accessible form; traceability enables authorities and operators to identify, contain, and withdraw affected product quickly.[34] The FSMP quality system should therefore connect lot release, ingredient batches, finished-product batches, destination country, local distributor, notified label version, complaints, and recall decision-making.

Launch gate: prove a mock recall across one batch in each regional supply chain before first commercial supply. The test should produce a complete consignee list and label-version history rapidly enough to support a targeted withdrawal.[34]

4. Reimbursement and formulary access are separate from regulatory access

The article now treats reimbursement, hospital formulary listing, tender qualification, and professional adoption as a separate market-access workstream.

Regulatory placement and payer or formulary access should be managed as separate launch decisions.

Launch gate: maintain a payer/formulary dossier distinct from the regulatory dossier: target patient population, clinical-nutrition evidence, comparator, budget impact, pricing, supply reliability, and local medical-affairs plan.

A 180-day practical workplan

Days 0–30 — classify and lock the proposition

Run a cross-functional classification workshop; obtain written local classification views for Wave 1; define the target population, nutritional requirement, claim matrix, and evidence gaps. Kill or redesign any product whose headline indication is actually a supplement or drug claim.[1, 10]

Days 31–75 — develop the regulatory-ready product

Freeze the formula and manufacturing process; build specifications, stability plan, supplier packages, risk assessment, master label, and core dossier. Initiate clinical work only when it is needed to support the product category or a priority-market dossier.[6]

Days 76–120 — localise and file

Appoint importers/representatives, complete registrations and notifications, translate artwork, validate nutrient calculations and allergens, and prepare country dossier modules. File China only when the core package and inspection readiness are complete.[6]

Days 121–180 — commercial readiness and lifecycle control

Finalise professional education that stays within the nutrition-management claim boundary, release first commercial batches, train medical affairs and distributors, and establish adverse-event/complaint, recall, product-change, and dossier-renewal governance.[6]

Governance: decisions that prevent rework

• Create a global classification board chaired by regulatory affairs, with medical, clinical nutrition, quality, R&D, and marketing sign-off.
• Make artwork a controlled regulatory document: one master claim library; no distributor-created local claims.
• Separate scientific substantiation from market authorization. An ingredient may be safe and a product may be clinically plausible, yet still fail category fit or local label rules.
• Use an approved-change matrix: formula, process, manufacturer/site, pack, label, target population, and claim changes should each trigger a jurisdictional regulatory assessment. China explicitly requires changes for formula/process modifications that may affect safety, nutritional adequacy, or special-medical-purpose effect.[6]

This is a strategic regulatory map, not legal advice. It is deliberately conservative where an exact local FSMP category or filing route did not surface in the initial official-source review. Before launch, validate the local category and filing procedure with the responsible authority or qualified local food-regulatory counsel.[10]